ARQULE/KYOWA HAKKO KOGYO SIGN ARQ 197 ASIA LICENSE.
ArQule, Inc. (NASDAQ: ARQL) Woburn, Mass., has entered into an
exclusive license agreement with Kyowa Hakko Kogyo Co., Ltd. (Kyowa) to
develop and commercialize ARQ 197, a small molecule, selective . . .
CHMP ADOPTS POSITIVE OPINION FOR ALEXION'S SOLIRIS IN
EUROPE.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), Cheshire, Conn., has
announced that the Committee for Human Medicinal Products (CHMP) of the
European Medicines Agency (EMEA) adopted a positive . . .
NEUROMED LICENSES PHASE 3 CHRONIC PAIN PRODUCT FROM ALZA.
Neuromed Pharmaceuticals Ltd., a biopharmaceutical company
developing next-generation chronic pain drugs, has licensed from ALZA
Corporation the exclusive U.S. rights to develop and . . .
TOPOTARGET UNVEILS AVUGANE PHASE II TRIAL FOR ACNE
VULGARIS.(Clinical report)
TopoTarget A/S (CSE: TOPO), Copenhagen, Denmark, has announced that
a Phase II clinical trial has been initiated, testing Avugane, a topical
valproic acid - an HDAC inhibitor drug - in the . . .
UCB INITIATES ADDITIONAL SHORT-TERM CLINICAL STUDY OF
CIMZIA.
UCB has initiated an additional short-term clinical study of CIMZIA
(certolizumab pegol) to confirm the induction of clinical response in
moderate to severe active Crohn's disease. UCB will work . . .
FIRST HEART ATTACK PATIENT ENROLLED IN RAPID MI-ICE
STUDY.
Cardium Therapeutics (OTCBB:CDTP), San Diego, Calif., and its
subsidiary InnerCool Therapies have enrolled the first patient in the
RAPID MI-ICE study at Lund University Hospital in Sweden. The . . .
BIOLINERX LICENSES PEPTIDE FOR INFLAMMATORY DISEASES.
BioLineRx Ltd.(TASE:BLRX), Israel's leading drug development
company, has signed a worldwide exclusive license agreement with Yissum
Research Development Company of the Hebrew University of . . .
GREEK MINISTRY APPROVES PRICE INCREASE FOR AMPHOCIL.
Samaritan Pharmaceuticals, Inc. (AMEX:LIV), Las Vegas, a developer
of innovative drugs, has received a price approval from the Greek
Ministry of Development for AMPHOCIL. This represents a . . .
SLOAN CANCER VACCINE PHASE III STUDY BEGINS.
Merck KGaA, Darmstadt, Germany, has announced that the first
patient has been enrolled in its global Phase III clinical study, START
(Stimulating Targeted Antigenic Responses To NSCLC), assessing . . .
SATRAPLATIN REDUCES RISK OF PROSTATE CANCER PROGRESSION.
GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index;
NASDAQ: GPCB) and Pharmion Corporation (NASDAQ: PHRM) have announced
that final progression-free survival (PFS) results for the . . .
EVOGENIX GRANTED US PATENT.
Antibody therapeutics company EvoGenix Ltd., Sidney, Australia, has
been awarded a patent by the US Patent Office (patent number 7,166,697)
covering its development and use of Evibodies(TM).
. . .
RUSSIAN MEDICAL ADVANCES SHOW UNPRECEDENTED ANTI-AGING.
Anti-aging medical breakthroughs that have taken more than 30 years
of research by some top Russian scientists will soon be making their way
to the United States. A team of top government . . .
FDA CLEARS BIOMS MEDICAL FOR PHASE III MULTIPLE
SCLEROSIS.
BioMS Medical Corp (TSX: MS), Edmonton, Canada, a leading developer
of products for the treatment of multiple sclerosis (MS), has received
clearance from the United States Food and Drug . . .
ARCHIMEDES PHARMA BEGINS PHASE III FOR NASALFENT.
Archimedes Pharma Ltd ("Archimedes"), a European
specialty pharmaceutical company, today announces the commencement of
its global Phase III programme for Nasalfent(r) in breakthrough cancer
pain.
. . .
ANECOVA UNVEILS NEW APPROACH FOR ASSISTED REPRODUCTION.
During a recent a press conference in Geneva, Martin Velasco,
Pascal Mock MD and Prof. Patrick Aebischer, president of the EPFL,
presented a solution which opens promising new prospects in terms . . .
DIGILAB'S PREP SERVICES USED FOR DIABETES RESEARCH.
A recent publication in a biotech journal acknowledges a Top 10
pharmaceutical company has utilized Digilab's sample preparation
and fractionation technologies to expose standard and novel . . .
APPROVAL FOR U.K. CLINICAL TRIAL FOR REOLYSIN.
Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC, NASDAQ:
ONCY), Calgary, Canada, has received a letter of approval from the U.K.
Medicines and Healthcare products Regulatory Agency (MHRA) for . . .
UCB GETS POSITIVE RESULTS FROM TWO CIMIZIA PHASE III
STUDIES.
UCB has announced positive top-line results for signs and symptoms
from two new phase III studies for CIMZIA(TM) (certolizumab pegol), the
first Fab' fragment anti-TNF (Tumor Necrosis Factor), in . . .
LIPOXEN SIGNS $75MIL PACT TO DEVELOP BLOOD CLOTTING
FACTORS.
Lipoxen PLC (AIM: LPX), London, U.K., has entered into an exclusive
worldwide development and license agreement with a subsidiary of Baxter
International Inc. to develop improved, longer-acting . . .
INEX'S CALIFORNIA HEARING RESCHEDULED TO JANUARY,
2007.
INEX Pharmaceuticals Corporation ("INEX"; TSX: IEX),
Vancouver, has announced that the British Columbia Supreme Court has
issued a favourable written ruling from the November 7 and 8, 2006
hearing . . .
|
|